Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

Chinese netizens question Japanese medicine quality following deaths linked to drugmaker's health supplements
Published on: 2024-03-28
Share to
User Rating: / 0
PoorBest 

A second fatality linked to supplements containing red yeast rice, or "beni-koji," manufactured by Japanese drugmaker Kobayashi Pharmaceutical has been confirmed in the wake of health issues arising from the ingredient, according to the country's health ministry.
 

The findings were disclosed by the Ministry of Health, Labor, and Welfare after questioning officials at the Osaka-based drugmaker, noting that details of the second death remained unclear. However, a doctor's written comment said the person suffered kidney damage.
 

According to the ministry, Kobayashi Pharmaceutical said that 106 individuals have been hospitalized upon consuming the supplements, with approximately 3,000 inquiries voicing health concerns received by the company's helpline.
 

As the health issue escalates, the Osaka city government on Wednesday issued recall orders for three products containing yeast-fermented rice subject to voluntary recalls, and according to local media reports, the city government plans to issue disposal orders after the completion of the process based on the Food Sanitation Act, suspecting harmful substances.
 

The pharmaceutical also announced the cancellation of its new employee ceremony scheduled for next Monday in the city of Osaka.
 

Chief Cabinet Secretary Yoshimasa Hayashi on Wednesday told a press conference that the incident "raised serious concerns about the safety of functional food products," national news agency Kyodo reported.
 

According to local media reports, it took Kobayashi Pharmaceutical over two months to disclose the damage they had been aware of, and the Consumer Affairs Agency plans to conduct an emergency inspection of over 6,000 functional foods.
 

The drugmaker's case marked the first of a manufacturer publicly announcing health damage and initiating voluntary recalls since the functional food labeling system was introduced in the country in 2015.
 

The beni-koji linked to health issues was manufactured at Kobayashi Pharmaceutical's Osaka factory. While the company suggested that unexpected mold-derived ingredients may have caused the problem, no specific cause has yet been identified.
 

日本又有2人服用小林制药红曲保健品后死亡总死亡人数升至4人

近日,日本药企小林制药含有红曲成分的保健品召回事件,引发关注。据总台环球资讯微博消息,服用小林制药红曲保健品的消费者死亡人数增至4人。
 

小林制药27日在官网上发布消息,将对相关消费者进行赔偿。小林制药公司公关部门工作人员表示:“针对日本国内,将根据商品种类和数量进行赔偿,一件商品赔偿2500日元(约合人民币120元)的代金券。针对中国大陆方面的赔偿问题,目前还在商议阶段,具体的一些情况,我们目前还无法回答。”
 

3月27日晚,小林制药(中国)有限公司发布协助小林制药株式会社自主召回使用红麹原料相关产品的声明称,本次自主召回涉及的三款产品均未在中国大陆市场上市销售,有中国消费者通过海外跨境平台、境外实体店铺或是其他渠道购买了相关产品,对此,小林制药将提供产品回收的协助。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2024 BusinessTianjin.com. All rights reserved.